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Introduction
Prostate cancer (PCa) is the most prevalent cancer in the 
western world for men and the second most common cause 
of death in men worldwide (1). Long-term follow-up from 
the European Randomised Study of Screening for Prostate 
Cancer (ERSPC) has shown a significant reduction in 
PCa specific mortality applying prostate-specific antigen 
(PSA) based screening (2). This, next to the fact that PSA 
is a well-developed, easy to implement, and cheap test, 
made PSA testing the mainstay in the decision for further 
Original Article
Head-to-head comparison of prostate cancer risk calculators 
predicting biopsy outcome
Nuno Pereira-Azevedo1,2*, Jan F. M. Verbeek1*, Daan Nieboer1,3, Chris H. Bangma1, Monique J. Roobol1
1Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands; 2Department of Urology, Centro Hospitalar do Porto, 
Porto, Portugal; 3Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands
Contributions: (I) Concept and design: N Pereira-Azevedo, JF Verbeek, MJ Roobol; (II) Administrative support: None; (III) Provision of study 
material or patients: N Pereira-Azevedo; (IV) Collection and assembly of data: N Pereira-Azevedo; (V) Data analysis and interpretation: JF Verbeek, 
D Nieboer, N Pereira-Azevedo, MJ Roobol; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.
*These authors contributed equally to this work.
Correspondence to: Dr. Nuno Pereira-Azevedo, MD. Department of Urology, Room NA-1706, P.O. Box 2040, Erasmus MC, University Medical 
Center Rotterdam, Rotterdam, 3000 CA Rotterdam, The Netherlands. Email: nuno@pereira-azevedo.com.
Background: Multivariable risk calculators (RCs) predicting prostate cancer (PCa) aim to reduce 
unnecessary workup (e.g., MRI and biopsy) by selectively identifying those men at risk for PCa or clinically 
significant PCa (csPCa) (Gleason ≥7). The lack of an adequate comparison makes choosing between RCs 
difficult for patients, clinicians and guideline developers. We aim to perform a head-to-head comparison of 
seven well known RCs predicting biopsy outcome. 
Methods: Our study comprised 7,199 men from ten independent contemporary cohorts in Europe and 
Australia, who underwent prostate biopsy between 2007 and 2015. We evaluated the performance of the 
ERSPC RPCRC, Finne, Chun, ProstataClass, Karakiewicz, Sunnybrook, and PCPT 2.0 (HG) RCs in 
predicting the presence of any PCa and csPCa. Performance was assessed by discrimination, calibration and 
net benefit analyses. 
Results: A total of 3,458 (48%) PCa were detected; 1,784 (25%) men had csPCa. No particular RC stood 
out predicting any PCa: pooled area under the ROC-curve (AUC) ranged between 0.64 and 0.72. The 
ERSPC RPCRC had the highest pooled AUC 0.77 (95% CI: 0.73–0.80) when predicting csPCa. Decision 
curve analysis (DCA) showed limited net benefit in the detection of csPCa, but that can be improved by a 
simple calibration step. The main limitation is the retrospective design of the study.
Conclusions: No particular RC stands out when predicting biopsy outcome on the presence of any PCa. 
The ERSPC RPCRC is superior in identifying those men at risk for csPCa. Net benefit analyses show that a 
multivariate approach before further workup is advisable.
Keywords: Prostate biopsy; prostate cancer (PCa); prostate-specific antigen (PSA); risk calculators (RCs); 
overdiagnosis
Submitted Dec 22, 2017. Accepted for publication Dec 22, 2017.
doi: 10.21037/tau.2017.12.21
View this article at: http://dx.doi.org/10.21037/tau.2017.12.21
26
19Translational Andrology and Urology, Vol 7, No 1 February 2018
Transl Androl Urol 2018;7(1):18-26tau.amegroups.com© Translational Andrology and Urology. All rights reserved.
clinical workup (i.e., prostate biopsy). However, any choice 
of a PSA cut-off involves a trade-off between sensitivity 
and specificity. Lowering the PSA cut-off would improve 
test sensitivity, but also reduce specificity, leading to far 
more false-positive tests and unnecessary interventions. 
Additionally, many of the cancers detected may never 
become clinically evident, thereby leading to overdiagnosis 
and overtreatment (3,4).
Other relevant pre-biopsy clinical information, next to 
the serum PSA level, has been incorporated into so-called 
risk calculators (RCs) to enable a more accurate assessment 
of a patient’s individual PCa risk (5). A recent systematic 
review identified 127 unique RCs in the field of PCa. The 
conclusion was that RCs outperform PSA alone in avoiding 
unnecessary biopsies, that not all of the RCs have the 
ability to selectively identify those men at risk of having 
clinically significant PCa (csPCa) (defined as Gleason score 
≥3+4) and that external validation studies and head-to-head 
comparisons are lacking (6). RCs are part of the European 
Association of Urology (EAU), European Society for 
Radiotherapy & Oncology (ESTRO), European Society of 
Urogenital Radiology (ESUR), and International Society 
of Geriatric Oncology (SIOG) joint guidelines on PCa 
screening and early detection (5) but it remains a matter of 
personal choice whether and/or which RC to use in one’s 
daily clinical practice.
We aimed to address this lack of information by 
evaluating the performance (discrimination, calibration, 
and clinical impact) of the most well-known RCs developed 
to predict prostate biopsy outcome in a head-to-head 
comparison.
Methods
Participants
Our study cohort comprises of 8,649 men from ten 
independent contemporary cohorts (nine in Europe and 
one in Australia) who underwent a transrectal ultrasound 
(TRUS)-guided prostate biopsy between January 2007 
and November 2015 (Table 1 and Acknowledgements). 
The cohorts were unrelated to the RCs development. Pre-
Table 1 Overview of the included predictors per RC to discriminate men at risk for any PCa and csPCa
Risk calculator PSA Age PV DRE Free PSA Fam. Race Prev Bx IPSS SD
Risk calculator, any PCa
ERSPC RPCRC + + + +
Finne + + + +
Chun + + + + +
Karakiewicz + + + +
PCPT 1.0 + + + +
PCPT 2.0 + + + + + +
PCPT 2.0 + freePSA + + + + + + +
ProstataClass + + + + +
Sunnybrook + + + + + + +
Risk calculator, clinical significant PCa 
ERSPC RPCRC + + + +
PCPT HG + + + + + +
PCPT 2.0 + + + +* + + +
Sunnybrook + + + + + + +
Age in years. *, Analysed PCPT 2.0 models with free PSA and without free PSA. csPCa, clinically significant prostate cancer; DRE, 
digital rectal examination suspicious or not; Fam, family history or not of prostate cancer; free PSA, free proportion of total PSA; IPSS, 
International Prostate Symptom Score (0–35); Prev bx, previous negative biopsy; PSA, prostate-specific antigen, in ng/mL; PV, prostate 
volume, in mL; SD, sample density (prostate volume/number of biopsy cores taken).
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biopsy clinical data and the pathological biopsy results 
were obtained from electronic and paper medical charts. 
Data on age, previous negative biopsy, DRE (digital rectal 
examination; benign/suspicious), prostate volume (assessed 
by TRUS in mL), total PSA (tPSA), free PSA (fPSA), and 
biopsy outcome (PCa detected yes/no and Gleason grade) 
were collected for all men. Patients were included into the 
analyses if they met the aggregated criteria of all RCs: age 
between 50 and 89 years old, PSA <50 ng/mL, prostate 
volume between 10 and 110 mL (Table S1). Participants in 
the study underwent a TRUS-guided biopsy according to 
the standard clinical practice used at each participating site, 
which was on average 12 cores [interquartile range (IQR): 
12–14] per biopsy session in the European cohorts and 
30 cores (IQR: 12–30) in the Australian cohort. 
Statistical analysis
Baseline characteristics of the study cohort are presented as 
median and interquartile range (M-IQR) or percentage for 
proportion type features. Missing data was imputed using 
Multivariate Imputation by Chained Equations (MICE) 
using only the values from the corresponding cohort 
and was imputed five times (7). Three parameters were 
completely missing in certain cohorts: fPSA (Den Bosch, 
Sydney, Breda), International Prostate Symptom Score (Den 
Bosch, Porto, Bordeaux, Munster, Paris, Hamburg, Rennes, 
Milan), and family history of PCa (Den Bosch, Porto, 
Bordeaux, Munster, Paris, Rennes). These missing values 
were imputed by using the complete information from the 
other cohorts in the imputation model. This strategy leads 
to more precise estimates of the predicted probabilities (8). 
After imputation, the probabilities were calculated on the 
basis of the predictions rules from each RC. Individual 
patient data was compared for men with csPCa and men 
without PCa using the Mann-Whitney test for continuous 
variables. 
Risk calculators
For this meta-analysis we included seven well known 
RCs: Chun (9), ERSPC Rotterdam Prostate Cancer Risk 
Calculator RPCRC (10), Finne (11), Karakiewcz (12), 
ProstataClass (13), Prostate Cancer Prevention Trial 
(PCPT) 1.0 and 2.0 +/– free-PSA (14), and Sunnybrook (15). 
The first six have been externally validated in over five 
studies (6). All RCs use PSA and DRE as a predictive 
factor, and the other predictors are displayed in Table 1. 
The RPCRC for initial and repeat biopsy (16) was adapted 
to the contemporary Rotterdam clinical setting (17). For 
each individual patient, the probabilities of having a biopsy 
detectable PCa and, if applicable, a csPCa, were calculated. 
The probabilities of the ProstataClass artificial neural 
network were obtained by sending a blinded database 
for PCa outcome to the ProstataClass developers (H. 
Cammann) (13). For uniform comparison between RCs 
men with a PSA above their advised cut-off for PSA (i.e., 
>20 ng/mL) were included (157 men (2.2% of the total 
cohort). Four models were able to separately predict csPCa 
(RPCRC, PCPT 2.0 +/– freePSA and Sunnybrook). 
Comparison of risk calculator models
The predictive accuracy (predicting PCa and csPCa) 
was quantified using the area under the curve (AUC) for 
the receiver operator characteristic (ROC) analysis (18). 
A multivariable meta-analysis was performed to pool 
the AUCs in predicting any PCa and csPCa. Within-
study correlations of the AUCs were estimated using 
bootstrapping. To analyze statistically significant differences 
in the models and taking into account the between-study 
heterogeneity we subsequently estimated the probability 
that a model has the highest AUC in a subsequent validation 
study. We simulated 10,000 samples from the posterior 
distribution to estimate this probability (19). Calibration 
of the RCs was pooled and explored graphically using 
calibrations plots. For comparison, the per center sensitivity 
and specificity of detecting csPCa with applying a PSA cut-
off ≥4.0 ng/mL was calculated and graphically displayed.
In addition, the clinical impact was assessed with decision 
curve analysis (DCA) and clinical impact curves. DCA 
represents the net benefit ratio, which weighs the benefits 
(detecting cancer) versus the harms (unnecessary biopsy) 
over a range of thresholds (20). Clinical impact curves show 
the estimated number who would be declared eligible for 
biopsy for each risk threshold and show the proportion 
of those who are cases (overall PCa and csPCa) (21). 
In addition, to show the potential of multivariate risk 
stratification when adapting to, for example, one’s own 
hospital data, we calculated net benefit after calibration of 
each of the 4 models predicting csPCa using the largest 
clinical cohort in our series (Den Bosch; N=2,053). Analyses 
were performed using R statistical package, version 3.3.1, R 
Foundation for Statistical Computing, Vienna, Austria. 
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Results
Of the total of 8,649 men 7,199 men (83.2%) were included 
in analyses. Median age was 65 years old, median PSA 
6.9 ng/mL, median prostate volume 45 mL (as evaluated by 
TRUS) and 1,496 men (21%) underwent a previous biopsy 
(Table 2). PCa was diagnosed in 3,458 of 7,199 patients 
(48%) and 1,784 (25%) men had csPCa. PCa patients were 
older (median age: 65 vs. 64 years for non PCa patients, 
P<0.001), had smaller prostate glands (41 vs. 50 mL, 
P<0.001), and higher PSA (6.7 vs. 7.0 ng/mL, P<0.001) 
(Table 3). 
In predicting any PCa no particular RC stood out and 
the pooled area under the ROC-curve (AUC) ranged 
between 0.64 and 0.72 (Figure 1) with Finne having the 
highest AUC. Substantial heterogeneity in the AUC was 
found between the different cohorts (range I2, 66–89%). 
In predicting csPCa the ERSPC RPCRC had the highest 
pooled AUC of 0.77 (95% CI: 0.73–0.80; Figure 1). After 
repeating this comparative analysis 10,000 times the ERSPC 
RPCRC had the highest probability (89%) of having the 
highest AUC. The probabilities of having the highest AUC 
in our study cohort were 6%, 3%, and 2% for PCPT 2.0 + 
freePSA, PCPT 2.0, and Sunnybrook RCs respectively. 
The calibration plots for those RCs predicting csPCa 
for the pan-European data set (including all cohorts except 
Sydney, Australia; n=6,665) are displayed in Figure 2. Three 
Table 3 Clinical characteristics of men with csPCa compared with 
men without PCa and lrPCa
Variable
No PCa,  
3,741 (52%)
lrPCa,  
1,674 (23%)
csPCa,  
1,784 (25%)
Age at 
biopsy 
(years) 
64 [59–68] 65 [60–69] 67 [62–72]
Total PSA 
(ng/mL) 
6.7 [5.0–9.2] 6.6 [5.0–9.0] 7.4 [5.4–11.6]
Free  
PSA rati 
0.16 [0.12–0.21] 0.14 [0.10–0.18] 0.12 [0.08–0.16]
Abnormal 
DRE
673 [18] 559 [33] 1,036 [58]
PV (mL) 50 [38–66] 41 [31–55] 39 [30–50]
Positive 
family 
history 
594 [16] 319 [19] 347 [20]
IPSS/AUA 3 [1–9] 2 [1–10] 3 [1–8]
Previous 
biopsy
977 [26] 316 [19] 198 [11]
Number 
of cores
12 [12–15] 12 [12–14] 12 [12–16]
Data are shown as median [IQR] or number [%]. csPCa, 
clinically significant prostate cancer; IPSS, International Prostate 
Symptom Score; IQR, interquartile range; lrPCa, low risk 
prostate cancer; PV, prostate volume. 
Table 2 Baseline characteristics of the independent cohorts
Cohort, city N of cases (%) Age, M-IQR PSA, M-IQR Abnormal DRE, N (%) Previous Bx, N (%) Any PCa, N (%) csPCa, N (%)
Porto*, PT 568 (7.9) 66 [61–70] 6.6 (4.8–8.9) 243 [43] 73 [13] 235 [41] 164 [29]
Bordeaux, FR 1,568 (21.8) 65 [61–69] 7.0 (5.4–9.5) 616 [39] 202 [13] 845 [54] 370 [24]
Paris, FR 116 (1.6) 65 [60–71] 4.4 (3.4–5.7) 38 [33] 16 [13[ 66 [59] 25 [24]
Rennes, FR 218 (3.0) 62 [58–68] 4.5 (3.4–5.8) 135 [62] 34 [16] 128 [59] 41 [20]
Milan, IT 715 (9.9) 65 [59–70] 6.1 (4.4–8.6) 128 [18] 246 [34] 281 [38] 135 [18]
Hamburg, DU 270 (3.8) 68 [62–71] 6.6 (4.6–9.5) 74 [27] 101 [37] 143 [52] 86 [31]
Munster, DU 513 (7.1) 63 [59–69] 5.2 (4.1–6.4) 59 [12] 211 [41] 253 [49] 213 [42]
Den Bosch, NL 2,053 (28.5) 64 [60–69] 7.9 (6.1–11.0) 566 [28] 428 [21] 847 [41] 368 [18]
Breda, NL 644 (9.2) 66 [62–71] 9.4 (6.9–13.5) 219 [32] 157 [24] 298 [47] 124 [20]
Sydney, AU 534 (7.4) 65 [58–69] 5.7 (4.1–8.3) 206 [39] 28 [5] 362 [68[ 258 [48]
Total 7,199 65 [60–69] 6.9 (5.1–9.6) 2,284 [32] 1,496 [21] 3,458 [48] 1,784 [25]
*, given their similar protocol, the 65 patients from Évora were included in the Porto cohort. Bx, biopsy; csPCa, clinically significant 
prostate cancer; DRE, digital rectal examination; M-IQR, median and interquartile range.
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models underestimated the probability of csPCa, while the 
ERSPC RPCRC was more accurate at low probabilities 
and mainly overestimated at probabilities >10%. Figure S1 
displays the decision curves and clinical impact plots per 
cohort applying the 4 RCs predicting csPCa. Overall the 
ERSPC RPCRC has the highest net benefit followed by the 
PCPT 2.0. Clinical impact is negligible to small starting at 
probabilities >10% for detecting csPCa. Figure S2 displays 
the differences in sensitivity and specificity of the PSA test 
(cut-off ≥4.0 ng/mL) per center. Sensitivity and specificity 
range from 76% to 98% and 4% to 44% respectively. Table 4 
shows net benefit when each of the 4 RCs are calibrated. 
At a 4% threshold for csPCa using the ERSPC RPCRC 
the number of biopsies can be reduced by 32% while 
keeping a 95% sensitivity for detecting csPCa. Reduction 
and sensitivity are 8% and 99% for PCPT2.0 + freePSA, 
16% and 97% for PCPT 2.0, and 25% and 95% for 
Sunnybrook.
Discussion
In this head-to-head comparison of seven well-known RCs 
predicting prostate biopsy outcome it is shown that all 
RCs have a moderate to well discriminatory ability when 
predicting any PCa (AUCs ranging from 0.64 to 0.72). 
Those RCs that can selectively predict csPCa show AUCs 
in the range of 0.71 to 0.77 with small clinical benefit in 
this pan-European cohort of contemporary daily clinical 
practice and clinical study data. Adjusting calibration 
shows the added value of incorporating multivariable risk 
prediction tools next to clinical expertise in clinical decision 
making. These results confirm earlier analyses on the use 
of multivariable prediction tools (6) and considering the 
substantial harm related to overdiagnosis of low risk PCa 
(3,22), the use of those RCs that selectively can predict 
csPCa is recommended.  
The balance between benefit and harm of early 
detection of PCa is still a topic of ongoing debate. Due 
to the initiation of PSA screening in combination with 
TRUS guided systematic prostate biopsy the incidence of 
predominantly low risk PCa increased enormously in the 
1990s. This eventually resulted in guidelines recommending 
no screening at all (23). However, with the available data 
from longitudinal studies and randomized PCa screening 
trials we currently have, the knowledge to improve the 
balance between harm and benefit recommendations have 
changed to using shared decision making with an individual 
approach towards how to screen best (24). 
While both discrimination and calibration are important 
statistics to evaluate performance of a prediction tool we 
must note that discrimination cannot be easily improved 
while calibration can (6). An example of potentially 
adjusting calibration to a particular setting is shown in (25) 
where a model was first tested using part of the available 
data (calibration phase) where subsequently performance 
was assessed in the rest of the data (validation cohort). 
Based on the wide calibration prediction intervals in the 
current analyses it is advisable to follow such an approach 
where the aim should be to assess moderate calibration on 
the basis of center specific retrospective data on prostate 
biopsy outcome with a minimum of 200 prostate cancers 
cases (26). Subsequently these center specific adjustments 
for the calculated probabilities could be incorporated, for 
example, in the RPCRC. It is in this context important 
to realize that when using a purely PSA based approach 
considerable variation in sensitivity and specificity also 
Figure 1 Meta-analysis of the pooled area under the curve (AUC) 
and 95% CI of various PCa risk calculators to discriminate men 
diagnosed with any prostate cancer (above) and clinically significant 
PCa (below). CI, confidence interval; PCa, prostate cancer.
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exists, as was shown in Figure S2, something that is ignored 
in recommendations on applying a cut-off value to trigger 
prostate biopsy.  
When predicting biopsy outcome, it must also be noted 
that especially the use of the multiparametric magnetic 
resonance imaging (mpMRI) in the detection of PCa and 
csPCa has increased considerably showing very promising 
results. However, while the mpMRI is advised to be used 
after a negative TRUS guided systematic prostate biopsy 
(often solely based on an elevated PSA level), the mpMRI 
is more and more used before the first biopsy (27). Previous 
analyses with the RPCRC have however shown that upfront 
risk stratification on the basis of easy (and cheap) to get 
relevant pre-biopsy information can avoid half of mpMRIs (17). 
This  s tudy has  some l imitat ions .  First ,  i t  i s  a 
retrospective study design using ten different cohorts from 
Figure 2 Pooled calibration plots for clinical significant prostate cancer using ERSPC RPCRC (A), Sunnybrook (B), PCPT 2.0 (C) and 
PCPT 2.0 + freePSA (D) risk calculators in the nine European cohorts. CI, confidence interval; free PSA, free proportion of total prostate-
specific antigen.
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populations with different background risk and different 
referral patterns (daily clinical practice cohorts with the 
risk of selective outcome reporting and clinical study 
cohorts with predefined eligibility criteria) as reflected 
in the heterogeneity of our results. On the other hand, 
evaluating performance of these RCs in this pan-European 
setting can be seen as a strength and support their use in 
Europe. Second, we mainly used the original RCs which 
were virtually all developed in the 1990s. This implies that 
they do not use later developed biomarkers (e.g., PHI, 
PCA3, the 4K panel). All these biomarkers have shown to 
have additional predictive value when incorporated into a 
prediction model and as such might be able to positively 
influence results (28-30). 
Finally, all RCs use as endpoint csPCa based on the 
original Gleason grading (31). It has been shown that 
the new Gleason grading system better reflects disease 
burden (32) as does the inclusion of cribriform growth 
patterns in the classification of Gleason 7 PCa (16,33).  
In conclusion, we performed the first head-to-head 
comparison of RCs predicting prostate biopsy outcome 
using a multicenter European and Australian population. 
No particular RC stood out in the discrimination of men 
with and without PCa. The ERSPC RPCRC showed 
highest discrimination when predicting clinically significant 
PCa. Net benefit in the available clinical cohorts was limited 
but can be increased by applying a simple calibration step. 
These outcomes support implementing next to clinical 
expertise a multivariable risk prediction tool before further 
workup (e.g., MRI and biopsy) in men suspicious for having 
a clinically significant PCa. 
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Threshold 4% 0.145
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PCPT 2.0 + freePSA 162 (7.9) 32 (6.7) 3 (0.8) 0.147
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Sunnybrook 516 (25.1) 105 (21.9) 20 (5.4) 0.145
Threshold 10% 0.088
ERSPC RPCRC 1,202 (58.5) 247 (51.6) 60 (16.3) 0.127
PCPT 2.0 + freePSA 890 (43.4) 216 (45.1) 61 (16.6) 0.103
PCPT 2.0 957 (46.7) 231 (48.2) 52 (14.1) 0.112
Sunnybrook 1,164 (56.7) 277 (57.8) 58 (15.8) 0.120
csPCa, clinically significant prostate cancer; PCa, prostate cancer.
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Supplementary
Table S1 Inclusion criteria of the different risk calculators
RC Age (years) N of biopsy cores PSA, ng/mL Prostate volume
ERSPC RPCRC 50–74 ≥6 <50 10–110 mL
Finne 55–67 ≥6 – –
Chun – ≥10 – –
Karakiewicz – ≥6 <50 –
PCPT 1.0 >55 ≥6 – –
PCPT 2.0 >55 ≥6 – –
ProstataClass <89 ≥6 <25 –
Sunnybrook – 12 <50 –
PSA, prostate-specific antigen.
Figure S1 Decision curve for the four models predicting clinically significant prostate cancer in all the individual cohorts (left panel) and 
clinical impact plots (right panel) for predicting clinical significant prostate cancer (csPCa) with the ERSPC RPCRC. Of the 1,000 patients, 
the black solid line shows the total number of men who would receive a biopsy for each risk threshold. The orange dashed line shows how 
many of those would be detected with any prostate and the black dashed line shows how many of those would be detected with csPCa. The 
space between the two dashed lines indicated the number of men with indolent PCa.
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Figure S2 Sensitivity and specificity per study cohort of the biomarker PSA applying a cut-off for biopsy of ≥4.0 ng/mL and predicting the 
presence of clinically significant prostate cancer (defined as GS ≥7). PSA, prostate specific antigen; GS, Gleason score.
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